What is the recommended treatment for Candida infection of the eye?

Treatment for Candida Eye Infection

For azole-susceptible Candida ocular infections, fluconazole (loading dose 800 mg, then 400-800 mg daily) or voriconazole (loading dose 400 mg IV twice daily for 2 doses, then 300 mg IV or oral twice daily) is the recommended systemic treatment, with liposomal amphotericin B (3-5 mg/kg IV daily) reserved for azole-resistant cases. 1

Treatment Algorithm Based on Disease Severity

Chorioretinitis WITHOUT Vitritis or Macular Involvement

• First-line systemic therapy:

  • Fluconazole: 800 mg loading dose, then 400-800 mg (6-12 mg/kg) daily, OR
  • Voriconazole: 400 mg (6 mg/kg) IV twice daily for 2 doses, then 300 mg (4 mg/kg) IV or oral twice daily 2

• Duration: 4-6 weeks minimum, guided by serial ophthalmologic examinations showing lesion resolution 2

• Critical caveat: Echinocandins have poor posterior chamber penetration and should be avoided for endophthalmitis, though they may be considered for asymptomatic, well-localized chorioretinitis if the isolate is echinocandin-susceptible 1

Chorioretinitis WITH Macular Involvement

• Systemic therapy PLUS intravitreal injection:

  • Same systemic regimen as above
  • PLUS intravitreal amphotericin B deoxycholate (5-10 μg/0.1 mL sterile water) OR voriconazole (100 μg/0.1 mL sterile water or normal saline) 2

• Rationale: Macular involvement requires immediate high-level antifungal activity to prevent irreversible vision loss

Endophthalmitis (Vitritis Present)

• Systemic therapy PLUS intravitreal injection:

  • Same regimen as macular involvement above 2

• Consider vitrectomy: Strongly recommended to reduce organism burden and remove fungal abscesses inaccessible to systemic agents 2

• Duration: Minimum 4-6 weeks, with final duration dependent on lesion resolution 2

Azole-Resistant Candida

For fluconazole/voriconazole-resistant isolates:

• Liposomal amphotericin B: 3-5 mg/kg IV daily
• Consider adding: Flucytosine 25 mg/kg orally 4 times daily 2

Recent case reports suggest intravitreal caspofungin (100 μg/0.1 mL) may be effective for multiresistant Candida when standard intravitreal agents fail 3, though this remains off-guideline.

Essential Management Principles

Multidisciplinary Approach

All treatment and surgical decisions must be made jointly by an ophthalmologist and infectious disease physician 2. This is a strong recommendation because:

• Ophthalmologists determine extent of ocular involvement (chorioretinitis vs. endophthalmitis, macular involvement)
• Infectious disease specialists guide systemic antifungal selection based on susceptibility patterns and pharmacokinetics

Mandatory Ophthalmologic Screening

• All patients with candidemia require dilated fundoscopic examination within the first week (preferably by an ophthalmologist) 2
• For neutropenic patients, delay examination until neutrophil recovery 2
• Serial examinations are essential to monitor treatment response 2

Source Control

If candidemia is present, central venous catheter removal is strongly recommended within 48-72 hours when safely feasible 1, 2

Evidence Quality and Guideline Comparison

The 2025 ECMM/ISHAM/ASM global guideline 1 represents the most current evidence and aligns closely with the 2016 IDSA guideline 2 on core treatment principles. Key updates in the 2025 guideline include:

• Explicit recommendation against echinocandins for endophthalmitis due to poor posterior chamber pharmacokinetics 1
• Allowance for echinocandins in asymptomatic, well-localized chorioretinitis with echinocandin-susceptible species 1
• Emphasis on liposomal amphotericin B formulations over amphotericin B deoxycholate when available 1

Recent observational data 4 confirms that endogenous Candida endophthalmitis (predominantly C. albicans) has better visual outcomes than exogenous infections, with final visual acuity of 20/63 vs. 20/3990 respectively. This underscores the importance of early systemic treatment in candidemia patients.

Common Pitfalls to Avoid

1. Using echinocandins for endophthalmitis: Despite their efficacy for candidemia, echinocandins penetrate poorly into the posterior chamber and should not be used for endophthalmitis 1

2. Delaying intravitreal therapy in severe disease: Macular involvement or vitritis requires immediate intravitreal injection in addition to systemic therapy 2

3. Inadequate treatment duration: Stopping therapy before complete lesion resolution (documented by serial ophthalmologic exams) leads to relapse 2

4. Failure to obtain susceptibility testing: Recent data shows increasing azole resistance, particularly in C. glabrata and emerging species like C. auris 5. Treatment must be adjusted based on susceptibilities 1

5. Missing the diagnosis: A 2021 study 6 found that critically ill patients, those with alcohol-related conditions, or poor prognosis were less frequently examined ophthalmologically, potentially missing ocular candidiasis